MedTrace Logo

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)

NCT04456088 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2021-01-22

No results posted yet for this study

Summary

The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.

Conditions

  • COVID-19
  • SARS-CoV 2
  • Respiratory Disease
  • Pneumonia, Viral
  • Corona Virus Infection

Interventions

COMBINATION_PRODUCT

150 ppm Nitric Oxide delivered through LungFit Delivery System

Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 150 ppm for 40 minutes 4 time per day plus standard supportive care.

COMBINATION_PRODUCT

80 ppm Nitric Oxide delivered through LungFit Delivery System

Nitric Oxide delivered via LungFit system. Patients will receive inhalations of 80 ppm for 40 minutes 4 time per day plus standard supportive care.

Sponsors & Collaborators

  • Beyond Air Inc.

    lead INDUSTRY

Principal Investigators

  • Asher Tal, MD · Beyond Air

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-15
Primary Completion
2020-11-15
Completion
2020-12-15

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04456088 on ClinicalTrials.gov